Immune Mediated Inflammatory Diseases (IMIDs) are a common and growing problem. Traditional models of research and service delivery silo their management within specific specialities and within adult or paediatric settings. Very often patients with disease in one organ have co-morbid involvement in another, suggesting shared pathogenic pathways. Moreover, IMIDs are often treated in very similar ways (combination therapy) with very similar drugs (steroids and anti TNF biologics). In this semin...